Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial

IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not been tested against an active comparator. OBJECTIVE: This trial assessed card...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA
Main Authors: Rosenstock, Julio, Kahn, Steven E., Johansen, Odd Erik, Zinman, Bernard, Espeland, Mark A., Woerle, Hans J., Pfarr, Egon, Keller, Annett, Mattheus, Michaela, Baanstra, David, Meinicke, Thomas, George, Jyothis T., von Eynatten, Maximilian, McGuire, Darren K., Marx, Nikolaus
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6763993/
https://ncbi.nlm.nih.gov/pubmed/31536101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2019.13772
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados